Biotech RadarJobs updated

COMPANY

Aegle Therapeutics

HQ: Woburn, MA source · aegletherapeutics.com ↗ · New England

Clinical Phase 2

Keywords: regenerative medicine rare disease dermatology rare diseases epidermolysis bullosa dystrophica Dystrophic Epidermolysis Bullosa Burns AGLE-102

Location: Woburn, MA · source · Aug 28, 2026

Profile checked Oct 10, 2026

2Trials (company is sponsor)

Funding and NIH signals

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

  1. Trial start Phase 1/Phase 2: MSC EVs in Dystrophic Epidermolysis Bullosa source ↗
  2. Trial start Phase 1: Safety of Extracellular Vesicles for Burn Wounds source ↗

Clinical trials (lead sponsor) 2

RecordTitlePhaseStatusStartPrimary completion
NCT04173650MSC EVs in Dystrophic Epidermolysis BullosaPhase 1/Phase 2RecruitingAug 13, 20242025-09 (estimated)
NCT05078385Safety of Extracellular Vesicles for Burn WoundsPhase 1CompletedAug 10, 2023Sep 5, 2024 (actual)
Feedback